Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfaller

Showing results (21-30 of 542) with videos related to

Pageof 55
Sort By:
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Susceptibility of clinical isolates of Candida spp. to terconazole and other azole antifungal agentsM A Pfaller, T Gerarden
Clinical Microbiology Reviews|July 1, 1988
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococciM A Pfaller, L A Herwaldt
Infectious Disease Clinics of North America|June 1, 1993
Antifungal susceptibility testing. Current state of technology, limitations, and standardizationM A Pfaller, M G Rinaldi
The Journal of Antimicrobial Chemotherapy|October 1, 1996
Standardization of antifungal susceptibility testingM G Cormican, M A Pfaller
Journal of Clinical Microbiology|November 18, 1998
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994M E Klepser, M A Pfaller
Diagnostic Microbiology and Infectious Disease|April 1, 1997
In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococciM A Pfaller, R N Jones
Journal of Clinical Microbiology|October 2, 2002
Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibilityM A Pfaller, D J Diekema
The Journal of Antimicrobial Chemotherapy|November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)M A Pfaller, R N Jones
Pharmacotherapy|August 15, 2001
In vitro antifungal susceptibility testingH L Hoffman, M A Pfaller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance programR N Jones, M A Pfaller
Pageof 55

Showing results (21-30 of 542) with videos related to

Sort By:
Pageof 55
Diagnostic Microbiology and Infectious Disease|November 1, 1989
Susceptibility of clinical isolates of Candida spp. to terconazole and other azole antifungal agentsM A Pfaller, T Gerarden
Clinical Microbiology Reviews|July 1, 1988
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococciM A Pfaller, L A Herwaldt
Infectious Disease Clinics of North America|June 1, 1993
Antifungal susceptibility testing. Current state of technology, limitations, and standardizationM A Pfaller, M G Rinaldi
The Journal of Antimicrobial Chemotherapy|October 1, 1996
Standardization of antifungal susceptibility testingM G Cormican, M A Pfaller
Journal of Clinical Microbiology|November 18, 1998
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994M E Klepser, M A Pfaller
Diagnostic Microbiology and Infectious Disease|April 1, 1997
In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococciM A Pfaller, R N Jones
Journal of Clinical Microbiology|October 2, 2002
Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibilityM A Pfaller, D J Diekema
The Journal of Antimicrobial Chemotherapy|November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)M A Pfaller, R N Jones
Pharmacotherapy|August 15, 2001
In vitro antifungal susceptibility testingH L Hoffman, M A Pfaller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance programR N Jones, M A Pfaller
Pageof 55